Piramal Healthcare is set to clinch yet another in-licensing deal. The company has concluded a marketing deal with US-based firm BioElectronics to market the latter’s pain management equipment, ActiPatch. The deal is likely to be announced sometime next month, sources said. Confirming this, Piramal Life Sciences vice-chairperson Swati Piramal said, “We have a strong marketing and distribution network and we are capitalising on that. We have a team that is continuously on the look out for such alliances. The product is going to be launched in August.” This alliance, she added, was solely a marketing one. BioElectronics is the developer and marketer of ActiPatch, a medical device which deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing of soft tissue injuries. Meanwhile, Piramal Healthcare on Tuesday said, it has joined hands with Pierre Fabre, a French-based company to launch ‘Ducray’, a range of dermo-cosmetic products. The two companies have invested INR 10 crore in setting up the required infrastructure in India. Since the products are derived from plants, the active plant ingredients will be made in France with the formulation done in India. This, Dr Piramal says, has helped to bring down the price of the products, the benefit of which will be passed on to the consumers. “The dermo-cosmetic market in India is new and nascent but has a lot of potential. So far there is no product in this category that is being sold. Since these products are non-schedule H they will only be sold on a prescription basis from dermatologists,” she said. Both companies, however, hope that in the near future, the products will be allowed to be sold over-the-counter. “We hope to reach a target of INR 20 crore in the next couple of years for these products. We also have plans to launch another 10-12 products in the coming years,” said Ducray Laboratories director Pierre Bottino.